The tumor suppressor gene von Hippel-Lindau (VHL) is involved in the development of sporadic clear-cell renal cell carcinoma (RCC). VHL interferes with angiogenesis and also controls cell adhesion and invasion. Therapies that target VHL-controlled genes are currently being evaluated in RCC patients. RCC is a immunogenic tumor and treatment with interleukin-2 (IL2) or interferon (IFN)-a results in regression in some patients. We used two renal tumor cell lines (RCC6 and RCC4) carrying VHL loss-of-function mutations to investigate the role of mutant VHL in susceptibility to natural killer (NK) cellmediated lysis. The RCC6 and RCC4 cell lines were transfected with the wild-type gene to restore the function of VHL. The presence of the gene in RCC cells downregulated hypoxia-inducible factor (HIF)-1a and subsequently decreased vascular endothelial growth factor (VEGF) production. Relative to control transfectants and parental cells, pVHL-transfected cell lines activated resting and IL2-activated NK cells less strongly, as assessed by IFNc secretion, NK degranulation and cell lysis. NKG2A, a human leukocyte antigen (HLA)-Ispecific inhibitory NK receptor, controls the lysis of tumor targets. We show that HLA-I expression in RCC-pVHL cells is stronger than that in parental and controls cells, although the expression of activating receptor NK ligands remains unchanged. Blocking NKG2A/HLA-I interactions substantially increased lysis of RCC-pVHL, but had little effect on the lysis of VHL-mutated RCC cell lines. In addition, in response to IFNa, the exponential growth of RCC-pVHL was inhibited more than that of RCC-pE cells, indicating that VHL mutations may be involved in IFNa resistance. These results indicate that a decreased expression of HLA-I molecules in mutated VHL renal tumor cells sensitizes them to NK-mediated lysis. These results suggest that combined immunotherapy with antiangiogenic drugs may be beneficial for patients with mutated VHL.
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Introduction
Metastatic renal cell carcinoma (RCC) of the clear-cell subtype is refractory to conventional chemotherapy. Until recently, after decades of drug testing, only interleukin-2 (IL2) and interferon (IFN)-a had been identified as having activity in RCC, with a 15% response rate (Negrier et al., 1998) . Consequently, these agents were the standard first-line treatments for metastatic RCC. High bolus doses of IL2 are effective for RCC patients with good predictive factors (Yang et al., 2003) , but also have serious side effects due to the leak syndrome. Furthermore, the mechanisms underlying the tumor regression are largely unknown and biological markers allowing identification of potential responders to immunotherapy are not available.
The identification of sentinel mutations driving carcinogenesis and malignant transformation is crucial for the development of targeted therapeutic strategies. Recent advances in the understanding of the biology and genetics of RCC have led to several novel targeted approaches, with unprecedented response rates (Rini et al., 2009 ). An early event during the evolution of clear-cell RCC is loss of function of the VHL gene, located on chromosome 3p and encoding a 213-amino acid protein (Latif et al., 1993) . Inheritance of a defective copy of the VHL gene leads to von HippelLindau (VHL) disease and is the most common cause of inherited clear-cell RCC (Gnarra et al., 1994) . In addition, up to 75% of patients with sporadic clearcell RCC have lost VHL (for example, chromosome 3p deletion, suppressed expression or loss-of-function base substitutions (Foster et al., 1994) ). Thus, loss of VHL function is an important sentinel event during RCC pathogenesis. The VHL gene is involved in several pathways linked to carcinogenesis, most notably the hypoxia-inducible pathway (Maxwell et al., 1999) . The major consequence of the loss of VHL function is continuous activation of hypoxia-inducible factors (HIFs), resulting in accumulation of HIF effectors and increased angiogenesis, cell growth, low oxygen survival and ultimately metastasis (Linehan et al., 2009) . VHL regulates the expression of genes coding for molecules involved in cell-cell contact (Aggelis et al., 2009) and that are implicated in the recognition and activation of immune cells, particularly natural killer (NK) cells.
NK cells are potent cytolytic effectors with role in innate and adaptive antitumor immune responses. NK cells kill tumor cells without prior sensitization and are believed to be the major source of IFNg in vivo; NKderived IFNg is crucial in priming T helper 1 responses (Martin-Fontecha et al., 2004) . NK cell activation depends on an intricate balance between activating and inhibitory signals that determine whether the target will be susceptible to NK-mediated lysis (Lanier, 2000; Moretta and Moretta, 2004) . Natural cytotoxicity receptors control NK cell activation: NKp46 and NKp30, expressed by resting NK cells, and NKp44, induced after stimulation by IL2. Although the ligands of natural cytotoxicity receptors are poorly defined, blocking of natural cytotoxicity receptors with specific antibodies confirms their involvement in the lysis of various tumor cells in vitro (Moretta et al., 2001) . Activation of NK cells is triggered by additional receptors. One such receptor, NKG2D, expressed by most peripheral NK cells, binds major histocompatibility complex (MHC)-related antigen (MIC)-A/B molecules and UL16-binding proteins (ULBPs), induced on membrane of stressed cells. DNAX accessory molecule 1 (DNAM-1), an adhesion molecule belonging to the immunoglobulin superfamily, promotes many NK functions in vitro. It has been reported that DNAM-1 is required for the elimination of tumor cells that express other NK cell-activating ligands only weakly (Gilfillan et al., 2008) NK cell activation is negatively controlled by inhibitory human leukocyte antigen (HLA)-I-specific NK receptors. KIR (killer Ig type receptor), expressed by NK subsets, recognize specific HLA-I alleles. The ubiquitous inhibitory C-lectin type CD94/NKG2A receptor is specific for HLA-E molecules; HLA-E present a restricted set of conserved nonameric peptides derived from the signal sequence of other MHC-I molecules (Braud et al., 1998) .
We previously showed that RCC cell lines are efficiently killed by patient NK cells (Gati et al., 2004) . RCC cells express activating NKG2D ligands and ICAM-1 that control NK-mediated lysis. However, expression of HLA-I molecules may override activating signals by engagement of CD94/NKG2A receptor and KIR. NK cells are not found in great numbers in advanced human cancers. However, they are numerous among tumor-infiltrating lymphocytes from RCC tumors, where they constitute a greater proportion than in peripheral blood lymphocytes (PBL) (Cozar et al., 2005) . The cytotoxic activity of the tumor-infiltrating lymphocytes mainly resides in the CD16 dim NK cell population that expresses CD94/NKG2A more strongly than the peripheral NK cells (Schleypen et al., 2003 (Schleypen et al., , 2006 . Moreover, the response to IL2 in RCC patients can be correlated with the extent of tumor infiltration by NK cells, showing NK cell importance in tumor control (Donskov et al., 2002) .
The role of VHL in the immunogenicity of renal tumors has never been studied experimentally. To elucidate the possible link between NK functionality and VHL gene status in RCC, we investigated how mutant VHL regulates the recognition and lysis of RCC cells by NK cells. We describe two cell lines carrying loss-of-function mutations in the VHL gene and restoration of wild-type VHL function by transfection. We report analyses of tumor phenotype, cytokine secretion and susceptibility to NK cell-mediated recognition of these various cell lines.
Results

VHL status of RCC cell lines and restoration of VHL function in pVHL transfectants
The entire coding sequence and the promoter region of the VHL gene in cell lines RCC4 and RCC6 were sequenced and mutations in exon 1 were thereby detected. RCC4 cells carry the mutation c.194C4G p.Ser65Trp, reported in a patient with VHL disease (VHL Mutation Database: http://www.umd.be:2020/). RCC6 cells carry the mutation c.331A4G p.Ser111Gly, previously identified in primary sporadic RCC (Whaley et al., 1994) . The second VHL alleles in both cell lines appear to have been deleted because both mutations and polymorphisms in the promoter are homozygous (data not shown). Both these mutations are at positions frequently mutated in RCC, and correspond to the b domain required for binding to HIF (Min et al., 2002) . HIF-1a and HIF-2a were constitutively expressed in RCC6 and hypoxia did not modify their expression whereas they were induced by hypoxia in control RCC7 cells, a cell line with a wild-type VHL gene ( Figure 1a ).
RCC4 cells were transfected with pcDNA3 (Maxwell et al., 1999) . RCC6 cells were transfected with a plasmid that contains the full-length cDNA coding for the VHL gene, pRC-HAVHL or with the empty vector pRC. RCC6-pE and RCC4-pE cells are the control transfectants (empty vectors) and RCC6-pVHL and RCC4-pVHL cells are those transfected with wild-type VHL. Stable transfection of RCC cells with VHL resulted in the loss of HIF-1a expression in basal conditions, whereaspE transfectants expressed HIF-1a constitutively ( Figure 1b ). To control VHL/HIF functionality, we evaluated vascular endothelial growth factor (VEGF) production by the various cell lines; VEGF secretion by RCC-pVHL cells was significantly lower than that by the corresponding RCC-pE cells ( Figure 1c) .
We also assessed the secretion of two cytokines overexpressed in RCC. IL6, an inflammatory cytokine that acts as a growth factor for renal cells, and the chemoattractant IL8, known to interfere with the recruitment of immune cells (Lahn et al., 1999) . RCC6 cells secreted high amounts of IL6 (42000 pg/ml) and IL8 (3000 pg/ml), and RCC4 cells produced 400 and 500 pg/ml of IL6 and IL8, respectively (Supplementary Figure 1) . The restoration of the VHL gene did not modify IL6 or IL8 secretion in these cell lines.
Restoration of wild-type VHL decreases NK cell-mediated lysis of RCC cells
The lytic potential of NK cells was measured by granule mobilization (CD107a staining) following stimulation by targets (Figure 2a ). With fresh NK cells, the percentages of CD107a þ cells were lower after exposure to RCC-pVHL cells than after exposure to RCC-pE cells. IL2-activated NK cells displayed greater degranulation and the weaker granule mobilization in response to -pVHL transfectants was maintained. NK-mediated lysis of RCC cell lines was assessed by xCELLigence, a label-free, real-time monitoring assay of adherent cell lysis by measuring impedance (Zhu et al., 2006; Urcan et al., 2009) . As shown in Figure 2b , NK-mediated lysis was 30-50% lower for the wild-type VHL transfectants than for the RCC-pE transfectants. Moreover, RCC6 cells were lysed at lower effector/target ratio than RCC4 cells, indicating that RCC6 is more susceptible to NKmediated lysis (Supplementary Figure 2) . The reduced susceptibility of RCC cell lines transfected with the wildtype VHL to lysis by NK cells indicates that the VHL mutations they carry, favor NK cell activation and promote NK-mediated lysis.
The activation of NK cells by target cells results in IFNg secretion (Figure 2c ). Fresh and IL2-activated NK cells secrete significant amounts of IFNg in response to RCC6 cell lines; resting NK cells responded better to RCC6-pE than to RCC6-pVHL. RCC4 cell lines did not induce IFNg secretion by fresh NK cells in five independent experiments (data not shown). IL2-activated NK cells secrete IFNg to RCC4 cells; the response toward RCC4-pE and -pVHL was dependent on donors NK cells.
Restoration of a wild-type VHL gene induces expression of HLA-I molecules by RCC cells We studied the expression of NK ligands by RCC-pE and RCC-pVHL cell lines: activating receptor ligands, adhesion molecules and MHC-I ligands of inhibitory NK receptors were analyzed (Figure 3) . Concerning NKG2D ligands, RCC6 and RCC4 cells express MIC-A strongly but less MIC-B. RCC6 cells express ULBP1, 2 and 3 molecules. In RCC4, only ULBP1 and 2 are expressed. RCC6 and RCC4 cell lines also expressed CD112 and CD155, the ligands of DNAM-1.
RCC6-pE cells expressed ICAM-1, N-CAM and VCAM-1 adhesion molecules (Figure 3b ). The signals for NCAM and VCAM-1 were stronger in RCC6-pVHL. RCC4-pE expressed ICAM-1 weakly and N-CAM and VCAM-1 were undetectable; the expression of ICAM-1 and VCAM-1 was stronger in RCC4-pVHL cells.
RCC6-pE and RCC4-pE cells strongly expressed classical HLA-I (HLA-A/B/C) molecules and pVHL transfection increased their surface expression (Figure 3c ). RCC6 cells lines also expressed the nonclassical HLA-G molecule, ligand of ILT2/ILT4/ KIR2DL4; the expression by RCC6-pVHL cells was weaker than that by RCC6-pE cells. HLA-E molecules, ligands of NKG2A, were not detected on RCC6-pE cells and were induced on RCC6-pVHL. Thus, the restoration of wild-type VHL function affects expression of HLA-I.
We further investigate whether the transfection of VHL affects HLA-I expression in a HIF-dependent manner. We performed small interfering RNA (siRNA) experiments to knock down HIF-1a (Figure 4 ). SiRNA-HIF-1a strongly inhibited the expression of HIF-1a in RCC6 cells, 24 h and up to 96 h after the transfection. This led to a modest and delayed increase of HLA-I molecules, most significant at 72-96 h (Figure 4a ). The HLA-I expression by RCC6 and RCC4-pE cell lines was assessed 96 h after the electroporation of siRNA ( Figure 4b ). As for RCC6, HIF-1a inhibition increased HLA-I expression in RCC4-pE cells. However, HLA-I membrane expression was faintly increased (Figure 4c ) compared with the increase induced by pVHL transfection.
Mutated VHL in RCC cells promotes NK cell activation through decreased expression of HLA-I molecules To determine the receptor/ligand interactions involved in IL2-activated NK-mediated lysis of RCC cells, we used real-time monitoring of cell lysis assays (xCELLigence) in presence of various mAbs to block receptor/ligand interactions. Results are expressed as percentages of lysis modulation compared with those in the presence of the isotype mAbs (Figure 5a) . The difference between -pE and -pVHL was maintained in all the experiments, although the variability between 
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A Perier et al donors contributed to substantial standard errors in the mean values. Anti-NKG2D mAb reduces the lysis of RCC-pE and -pVHL cell lines by 30 and 40%, respectively, indicating that NK-mediated lysis mainly involves NKG2D (Figure 5a ). Anti-natural cytotoxicity receptor mAbs (NKp30) diminished the lysis of RCC6-pE cells by 13% and RCC6-pVHL cells by 37%. Consistent with the strong expression level of HLA-I and HLA-E molecules by RCC-pVHL, the addition of NKG2A or HLA-I-specific mAbs dramatically increased NK-mediated lysis of RCC-pVHL cells. In contrast, these mAbs had only a very small effect on the lysis of RCC-pE cells, indicating an expression of HLA-I, too low to counteract the activating receptors on mutated VHL cell lines. Figure 5b shows a representative experiment of the dynamic lysis of RCC-pE and -pVHL cells by IL2-activated NK cells in the presence of NKG2D and NKG2A mAbs. A similar pattern of modulation was observed for NK cell degranulation (Supplementary Figure 3) . The effects of various mAbs on IFNg secretion by NK cells were also determined (Figure 6 ). Blockade of NKG2D, NKp30 and NKp46 decreased IFNg secretion, indicating that they control IFNg secretion by IL2-activated NK cells. As for cell lysis, the involvement of NKp30 in NK activation was larger for RCC6-pVHL (37%) than for RCC6-pE (17%). Addition of NKG2A or HLA-I-specific mAbs substantially increased IFNg secretion by NK cells in response to RCC-pVHL cells. Thus, the lower NK-mediated lysis of RCC-pVHL than RCC-pE is associated with a shift toward inhibition induced by the stronger expression of HLA-I molecules. The observation that anti-HLA-I and anti-NKG2A mAbs affect NK function to a similar extend toward RCC6-pVHL cells, may reflect their expression of HLA-E. The greater NK activity toward RCC4-pVHL in presence of anti-HLA-I than in presence of anti-NKG2A suggests the involvement of additional NK receptors (such as KIRs). These findings indicate that certain VHL gene mutations favor NK cell activation by RCC cells through the decreased abundance of HLA-I molecules.
Responses to IFNs of RCC-pE and RCC-pVHL cells
IFNa and IFNg control the expression of HLA-I and adhesion molecules by tumor cells. We therefore evaluated the effects of these cytokines on the phenotype 
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A Perier et al of RCC cell lines. RCC cells were stimulated for 48 h with 1000 U/ml of IFNs, and this strongly induced HLA-I molecules (mean fluorescence intensity (MFI) fold increase 45) on RCC6-pE and RCC4-pE cells (Figure 7 ). The magnitude of HLA-I induction was lower (MFI fold increase o3.5) for RCC6-pVHL and RCC4-pVHL cells, leading to similar HLA-I levels onpVHL and -pE cells treated with IFNs. IFNg induces HLA-E in RCC6 and RCC4 cells, resulting in similar levels of HLA-E on -pE and -pVHL cells. IFNa slightly increased HLA-E expression by RCC6 cell lines but not by RCC4. IFNa and IFNg induced HLA-G on RCC6-pE not on RCC6-pVHL; there was no HLA-G induction on RCC4 cell lines. IFNg also induced ICAM-1 and VCAM-1 in -pE and -pVHL cells, but the expression of CD56 remained unchanged (data not shown). IFNs treatment had no significant effect on either NKG2D or DNAM-1 ligand expression by RCC cells (data not shown). In addition, RCC-pE and -pVHL cells secreted small amounts of soluble HLA-E molecules (10-40 pg/ml), that was increased after treatment with IFNs (data not shown). IFNa is a recognized treatment for metastatic RCC, so we assessed the proliferation of RCC cells in response to IFNa by dynamic analysis of the cell index by xCELLigence (Figure 8) . IFNa inhibited the proliferation of RCC cells in a dose-dependent manner (Figure 8a ). Low doses of IFNa inhibited the growth of RCC-pVHL cells more efficiently than the growth of RCC-pE cells (Figure 8b ). This suggests that the mutant VHL may contribute to RCC cell resistance to IFNa in RCC cells.
Discussion
To facilitate the development of integrated immune targeted therapy, it is necessary to reconsider the role of the NK cell in tumors, taking in account the involved mechanisms leading to carcinogenesis. Here, we report investigations of how genetic alteration of the VHL gene determines renal tumor cell immunogenicity, by evaluating the consequences on NK cell activation of a restored wild-type VHL in two RCC cell lines carrying VHL mutations. The missense mutation in RCC6 and RCC4 cell lines is in the sequence coding for the b domain of VHL that interacts with HIF-1a. The transfection of these cell lines with a wild-type VHL restored the control of HIF-1a expression and had an unexpected effect on immunogenicity of RCC cells. Analyses with parental RCC6 cells that behave as pE transfectants further supported the involvement of VHL in NK cell activation (data not shown).
We show that the restoration of VHL function decreased the susceptibility of the two distinct RCC cell lines to lysis by IL2-activated NK cells, indicating that the VHL gene mutations carried by these RCC cells favor NK activation. We found that VHL controls NKmediated lysis and IFNg secretion through modulation of HLA-I expression. In addition, the regulation of IFNg secretion is different in RCC4 or RCC6 cell lines. RCC6 but not RCC4 cells, induced IFNg secretion by fresh NK cells. The engagement of the activating receptor KIR2DL4 by HLA-G expressed by RCC6 may be involved (Rajagopalan et al., 2001) , although addition of anti-HLA-G mAbs had no clear effect on IFNg secretion (data not shown). The response toward RCC4-pE and -pVHL was dependent on donors NK cells. These results suggest that distinct pathways are involved in IFNg release and cytotoxicity (Chuang et al., 2001; Reefman et al., 2010) , and complex interactions between activating and inhibitory receptors account for the global response of heterogeneous NK cells. Moreover, we showed that NKp46 is more involved in IFNg secretion than in cytotoxicity.
The main characteristic of RCC cells compared with their pVHL transfectants is a substantially lower expression of HLA-I molecules. Altered expressions of HLA-I and HLA-E molecules by parental and RCC-pE cells, and the results of blocking experiments, suggest that VHL is responsible for the susceptibility of these cells to NK-mediated lysis. The previously reported expression of HLA-G by RCC6 (Ibrahim et al., 2001 ) is decreased by transfection with the wild-type VHL gene, in agreement with the link between HIF-1 stabilization and HLA-G expression by melanoma cells (Mouillot et al., 2007) and trophoblast (Kilburn et al., 2000) . Transfection with the wild-type VHL had no effect on the expression of ligands for NKG2D and DNAM-1 activating NK receptors. Blocking experiments indicated that of the activating receptors only NKp30 may differently affect lysis of RCC-pE and -pVHL cells. The adhesion molecules ICAM-1 and VCAM-1 were upregulated in RCC-pVHL cells. Strongly expressed by RCC-pVHL cells, these adhesion molecules may contribute to the magnitude of the NK/RCC target conjugates (data not shown). However, they appear to interfere with NK cell activation only weakly as blocking ICAM-1 (by anti-LFA-1) had a minimal effect on NK cell-mediated lysis (data not shown).
We showed that HIF-1a extinction induced a weak and delayed increase of HLA-I expression, suggesting that HIF-1a affect HLA-I expression through the involvement of intermediates. Our results are in accordance with previous reports showing that HIF-1a stabilization in VHL-deficient cell lines and clear-cell RCC results in the repression of endogenous signal transducer of activation of transcription (STAT)1 mediated by stimulated with retinoic acid (STRA)13 (Ivanova et al., 2001; Ivanov et al., 2007) . STAT-1 regulates the constitutive expression of LMP2, a protein implicated in HLA-I antigen presentation (ChatterjeeKishore et al., 2000) likely responsible for the modulation of the HLA-I expression. Moreover, HLA-E promoter contains a STAT1 binding site (Gobin and van den Elsen, 2000) . Interestingly, as the extinction of HIF-1a restored a modest HLA-I induction, our results indicate that mutation of VHL in RCC cells may also control HLA-I expression in a HIF-1a-independent manner. This suggests new additional HIF independent functions of VHL linked to immunogenicity.
With a weak HLA-I expression controlled by altered/ mutated VHL, RCC-pE cells should therefore be closer to the threshold where the balance between activation and inhibition can be shifted. By contrast, RCC-pVHL transfectants express HLA-I molecules strongly, tipping the balance toward the inhibitory pathway, and they therefore appear to be normalized by the restored VHL function. Thus, changes in the ratio of activating to inhibitory ligands on these cells can have a very large effect on their recognition by NK cells. Differences in HLA-I expression between cancer cells and the normal surrounding tissue are frequent and are involved in the immune escape and tumor progression. RCC is known 
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A Perier et al to downregulate HLA-I and II genes (Osborne et al., 1997; Atkins et al., 2004; Zagzag et al., 2005) . Abnormalities in the expression of HLA molecules altering antigen presentation may contribute to tumors evading the adaptive immune response (Seliger et al., 2000) , but promote NK activation. Renal tumors produce additional factors that may favor their infiltration by NK cells, consistent with NK cells having a role in RCC. Strong secretion of IL6 by RCC cells may favor tumor growth (Alberti et al., 2004) , but induce an inflammatory environment and recruit NK cells (Wysocki et al., 2010) . The chemoattractant cytokine, IL8, in the environment of renal tumors may also favor the recruitment of NK cells (Segerer et al., 2006) and induce their activation together with the membrane IL15 present on renal cells (Wittnebel et al., 2007) .
RCC4-pE and RCC6-pE cells proliferation is faintly altered by IFNa while the cytokine exert a larger antiproliferative effect on -pVHL transfectants, suggesting that responses to IFNs may be influenced by the VHL status, and calling the attention to fine-tuning of the biotherapy of RCC (IFN) in a 'targeted' manner (Kopper and Timar, 2006) . We report our original data providing evidence that mutant VHL, as found in most sporadic RCC, triggers NK cell activation. Although the correlation between VHL alteration in sporadic RCC and better survival is still controversial (Yao et al., 2002; Banks et al., 2006; Smits et al., 2008) , the absence of VHL mutation is associated with tumor aggressiveness and poor survival (Patard et al., 2008 (Patard et al., , 2009 . Our evidence that NK cells are activated differently by targets that bear or not VHL mutations are consistent with earlier findings that suggest that somatic VHL alteration is associated with better cancer-specific survival among those patients presenting with early stage (pT1 and pT2) clear-cell RCC (Parker et al., 2005) . Strong expression of the cancer antigen, carbonic anhydrase IX, associated with VHL loss of function (Grabmaier et al., 2004) is correlated with a greater spontaneous immune response Mutated VHL RCC cells and NK cell activation A Perier et al leading to a better outcome in some cases. Furthermore, carbonic anhydrase IX expression strongly predicts the response to IL2-based immunotherapy in metastatic clear-cell RCC (Atkins et al., 2009) . These results suggest that determination of the VHL gene status in sporadic RCC patients may help choose the appropriate therapeutic strategy because certain VHL mutations may condition RCC immunogenicity.
Materials and methods
Cells and treatments RCC6 and RCC7 cells derived from clear-cell renal tumors were described previously (Viey et al., 2005) . Stable transfectants were generated from RCC6 by transfection with pRC-HAVHL or the empty vector, pRC, using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), and followed by selection with G418 (3 and 1 mg/ml, respectively). RCC4-pE and RCC4-pVHL cell lines (provided by Dr N Rioux) were cultured with 0.5 mg/ml of G418. NK cells were purified from peripheral blood mononuclear cells (PBMC) by negative immunoselection using an NK selection kit (Miltenyi Biotech, Paris, France) and were cultured with IL2 (10 ng/ml, R&D Systems, Lille, France) for 6-12 days.
To produce hypoxic conditions, cells were incubated in a chamber in the atmosphere containing 0.5% O 2 , 5% CO 2 and 94.5% N 2 at 37 1C for 20 h.
To knock down HIF-1a, RCC cells were electroporated with the ON-TARGETplus SMARTpool SiRNA targeting HIF-1a and the non-targeting pool as a negative control (Dharmacon, Austin, TX, USA); 10 6 cells were nucleofected using the Nucleofector Kit V (Amaxa Biosystems, Gaithersburg, MD, USA) with 1 mM of siRNA.
VHL sequencing A DNA Tissue mini kit (Qiagen, Courtaboeuf, France) was used according to the manufacturer's protocol to extract genomic DNA from RCC cells. The three VHL coding exons, with exon-intron junctions, and promoter region, were screened for mutations by direct sequencing as previously described with primers available on request (Gad et al., 2007) .
Protein extraction and western blotting Cells were lysed in NP40 buffer (phosphate buffered saline, 1% Triton, 2 mM EDTA, 50 mM NaF, protease inhibitors cocktail (Roche, Laval, Canada)), sonicated and centrifugated 30 min at 20 000 g. Proteins were separated by SDS-PAGE, electrotransferred onto PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA) and visualized by chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA). We used anti-HIF-1a (54/HIF-1a, BD Pharmingen, San Diego, CA, USA), anti-HIF-2a (ab199, Abcam, Paris, France) and anti-HLA-I (HC-10). Anti-HA, anti-actin, anti-b-tubulin and secondary peroxidase-conjugated antibodies were from Santa Cruz (Heidelberg, Germany).
Measure of VEGF secretion by RCC cell lines
In total, 1 50 000 cells were cultured in 6-well plates in 2 ml of serum-free medium for 24 h. Cytokine concentrations in the supernatant were determined using ELISA assays from R&D Systems. Comparisons of mean values between groups were performed using unpaired t-test: **0.001oPo0.01, *0.01oPo0.05.
Phenotype analysis RCC cells were grown for 48 h in serum-free medium supplemented with or without 1000 U/ml of IFNa (Roferon, Roche) or IFNg (Miltenyi Biotech), stained and analyzed in a FACSCalibur cytometer (Becton Dickinson, Lincoln Park, NJ, USA). We used the following antibodies: conjugated anti-CD54, anti-CD56, anti-HLA-ABC (B9.12.1) and anti-CD112 from Beckman Coulter (Villepinte, France); anti-CD155 (R&D Systems), unconjugated anti-HLA-G (87G) and anti-HLA-E (MEM/E-08) from Exbio (Vestec, Czeck Republic); anti-MIC-A, MIC-B, -ULBP1, -ULBP2, -ULBP3 and -VCAM-1 from R&D Systems; secondary antibodies from Jackson ImmunoResearch (Suffolk, UK).
Measure of IFNg secretion and degranulation by RCCstimulated NK cells NK cells (10 5 cells) were co-cultured for 4 h with RCC cells at a 1/1 effector/target ratio in the presence of IL2 (10 ng/ml). IFNg concentration was measured in supernatants using a Duoset ELISA kit (R&D Systems). To measure NK cell degranulation, cells were labeled with CD107a-FITC (BD Pharmingen) and CD45-APC (Beckman Coulter). Some cocultures were performed in the presence of 10 mg/ml of the following mAbs or isotype controls: NKG2D, NKG2A, NKp30, NKp46, DNAM1 (R&D Systems), HLA-ABC (B9.12.1), HLA-G (87G) and HLA-E (MEM/E-08); mAbs were pre-incubated with NK cells (or with target cells for HLA-I blocking) for 15 min before the co-culture. Comparisons of mean values were performed using Wilcoxon matched pairs test and Po0.05 was regarded as significant.
xCELLigence assays
The xCELLigence System (Roche) monitors cellular events in real time without the incorporation of labels. It measures electrical impedance across interdigitated micro-electrodes integrated on the bottom of tissue culture E-Plates. The impedance measurement provides quantitative information about the status of the adherent cells, including cell number, viability and morphology. For cell-mediated lysis assays, adherent targets (5000) were seeded into the wells of 96 Â E-Plates in 100 ml of medium. Cell adhesion and growth were monitored for 4 h. NK cells were added to various concentrations in a volume of 50 ml per well. Co-cultures were assessed by the system with a measure every 5 min for up to 20 h. Results, expressed as cellular index (CI), were normalized with RTCA Software (Roche, Applied Science, Mannheim, Germany) (nCI), and are expressed as percentage of specific lysis: % lysis ¼ (nCI (no effector)ÀnCI (effector))/nCi (no effector) Â 100.
To evaluate the effect of IFNa on RCC cell lines, 2500 cells per well were seeded and allow adhering for 3 h. Various concentrations of IFNa were added and cell proliferation was monitored for up to 3 days. The CI was normalized and percentage of inhibition was calculated during the exponential growth phase.
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